I would say the cost to capture patients in the UK may be higher than Australia.
If Althea try to scale their business, they would be scaling their losses.
I guess this is what you get when you get a group of people with minimal pharma experience running a pharmaceutical business.
AGH's stock price is pretty much the lowest price it has ever been in the last 15 months for a reason. IMHO, I see the best solution is sacking the existing management and bringing in experienced pharma execs to replace the existing crew.
I would say the cost to capture patients in the UK may be higher...
Add AGH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
0.001(2.50%) |
Mkt cap ! $8.309M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.1¢ | 2.0¢ | $1.654K | 81.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 2783673 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 809218 | 6 |
View Market Depth
| Last trade - 15.46pm 09/09/2024 (20 minute delay) ? |
| AGH (ASX) Chart |